Citrulline and Arginase Activity in Severe Sepsis and Septic Shock

Sepsis Clinical Trial

— CARS  

Official title:

Activity and Expression of Plasma Arginase in Patients With Severe Sepsis or Septic Shock as Prognostic Value

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03837730
• Other study ID #: P/2018/353
• Status: Not yet recruiting
• Start date: February 10, 2019
• Est. completion date: August 10, 2019

Study information

• Verified date: January 2019
• Source: Centre Hospitalier Universitaire de Besancon
• Contact: Gaël PITON, MD
• Phone: 381668127
• Email: gpiton[@]chu-besancon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Sepsis is an acute pathology defined as an inappropriate response of the host to infection, resulting in the onset of organ failure (Quick SOFA ≥2, or SOFA ≥2). Septic shock is a sepsis associated with an elevation of lactate ≥ 2 mmol / l and an arterial hypotension requiring vasoactive drugs. Several studies highlighted that sepsis is associated with a plasma L-arginine deficiency. This deficiency induces a lower availability of L-arginine for multiple metabolic pathways including those involved in the synthesis of nitric oxide (NO) in the vascular endothelium via NO synthase. NO is the main endogenous vasodilator mediator, a lower synthesis induces a vascular and endothelial dysfunction that can promote the occurrence of an organic dysfunction during sepsis. Decrease in available NO was confirmed in patients with sepsis and appears correlated with severity.

L-arginine deficiency can have multiple origins:

• L-arginine deficiency resulting from a decrease in endogenous production from citrulline synthesized by the enterocytes. Such enterocyte dysfunction has been confirmed in patients with sepsis and is characterized biologically by elevated plasma levels of I-FABP (intestinal fatty acid binding protein - enterocyte-specific protein, cytolysis marker) and lower than that of citrulline (hypocitrullinemia, marker of lower activity).

• L-arginine deficiency may also result from a catabolism increase via arginase activity increased. This ubiquitous enzyme, having 2 isoforms (Arg1 and Arg2), allows the synthesis of urea and ornithine from L-arginine. An increase in arginase activity would decrease the available reserves of L-arginine for NO synthesis.

The objectives of this work is to evaluate, in patients with severe sepsis or septic shock, the prognostic value of the plasma arginase activity and the plasma expression of 2 isoforms Arg1 and Arg2, their kinetics, and the link between activity / expression of arginase and enterocyte dysfunction.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 118
• Est. completion date: August 10, 2019
• Est. primary completion date: May 10, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years old or older

• Patient admitted to ICU

• Diagnosis, suspected or confirmed, of severe sepsis or septic shock

• Expected ICU stay of at least 2 days

• Affiliation to a social security system or recipient of a such system

• Signed informed consent

Exclusion Criteria:

• Pregnancy

• Chronic intestinal pathology

• Chronic renal failure defined by creatinine clearance <50 ml / min / 1.73m2 (CKD-EPI)

• Severe hepatic insufficiency (Child-Pugh stage C score)

• Legal incapacity or limited legal capacity

• Subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator

• Patient within the exclusion period of another study or planned by the "national file of volunteers"

Related Conditions & MeSH terms

• Biomarkers
• Infection
• Intensive Care Units
• Sepsis
• Septic Shock
• Shock
• Shock, Septic
• Toxemia

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Besancon

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	prognostic value of plasma arginase activity and expression at ICU admission in patients with severe sepsis or septic shock	activity / expression of plasma arginase at ICU admission and 28-day mortality rate from admission to intensive care	28 days
Secondary	activity / expression kinetic of plasma arginase	3 points kinetic : admission, day 3 and day 7	during the first 7 days of ICU admission
Secondary	prognostic value of enterocyte damage	at ICU admission and 28-day mortality rate from admission to intensive care	28 days